Oncolix

About:

Oncolix is a clinical-stage bio-pharmaceutical company developing a therapeutic protein for the treatment of cancer.

Description:

Oncolix is a clinical-stage biotechnology company that is focused on cancer. The company is currently conducting a Phase I clinical trial for the indication of ovarian cancer. The drug, Prolanta, is a prolactin receptor antagonist. The mechanism of action is autophagocytosis or autophagy.

Total Funding Amount:

$8.46M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Houston, Texas, United States

Founded Date:

2007-01-01

Contact Email:

mredman(AT)oncolixbio.com

Founders:

Number of Employees:

11-50

Last Funding Date:

2015-01-22

IPO Status:

Private

Industries: